Results 171 to 180 of about 2,751,693 (208)
Some of the next articles are maybe not open access.

Resistance to Imatinib: Mechanisms and Management

Journal of the National Comprehensive Cancer Network, 2005
Imatinib, a specific small molecule inhibitor of the Abl kinase, has become the standard drug therapy for chronic myelogenous leukemia in all phases. More than 80% of newly diagnosed patients with chronic phase attain a complete cytogenetic response (CCR).
openaire   +2 more sources

Imatinib Is a Substrate for Various Multidrug Resistance Proteins

Blood, 2008
Abstract An increasing resistance to imatinib is an emerging problem in patients with chronic myeloid leukemia. The aim of the study was assessing possible mechanisms of cellular drug resistance in imatinib-resistant derivates of chronic myeloid leukemia K-562 cell line.
K, Czyzewski, J, Styczynski
openaire   +2 more sources

Resistance to Imatinib Mesylate in Chronic Myeloid Leukaemia

Cancer Letters, 2007
Despite the remarkable results achieved with imatinib for the treatment of chronic myeloid leukaemia, the emergence of resistance to this tyrosine kinase inhibitor has become a significant problem. Much progress has been recently made in elucidating the mechanisms which underlie imatinib resistance.
Charles Chuah, Junia V Melo
exaly   +3 more sources

Overcoming imatinib resistance

Blood, 2004
The remarkable success of imatinib in the treatment of chronic myelogenous leukemia (CML) is perhaps the most convincing example of effectiveness of a molecularly targeted therapy in a human malignancy. However, resistance to imatinib can be a problem.
openaire   +1 more source

Comparison of Imatinib, Dasatinib, Nilotinib and INNO-406 in Imatinib-Resistant Cell Lines.

Blood, 2007
Abstract Second-generation ABL tyrosine kinase inhibitors (TKIs) such as dasatinib, nilotinib and INNO-406 (formerly NS-187) have been developed to override imatinib-resistance mechanisms. We directly compared the growth-inhibitory effects in imatinib-sensitive and -resistant CML cell lines and the inhibitory profile for SRC family ...
Yasuyuki, Deguchi   +6 more
openaire   +2 more sources

Cytogenetic and molecular mechanisms of resistance to imatinib

Seminars in Hematology, 2003
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (Gleevec) (formerly STI571) is a promising new therapeutic strategy in patients with chronic myelogenous leukemia (CML). Despite significant hematologic and cytogenetic responses, resistance occurs in patients with chronic phase (CP) and advanced disease.
openaire   +2 more sources

Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CML

Acta Haematologica, 2012
Imatinib resistance is an important hurdle in the treatment of chronic myeloid leukemia (CML), and CML patients with this drug resistance are often given a dismal prognosis. In this case report, an imatinib-refractory blast phase CML patient was treated with a combination of imatinib and nilotinib.
Guang-Rong, Zhu   +7 more
openaire   +2 more sources

Imatinib resistance in multidrug-resistant K562 human leukemic cells

Leukemia Research, 2009
The multidrug resistance phenotype (MDR) is one of the major causes of failure in cancer chemotherapy and it is associated with the over-expression of P-glycoprotein (P-gp or MDR1) in tumor cell membranes. A constitutive NF-kappaB activity has been observed in several haematological malignancies and this is associated with its anti-apoptotic role.
Yanina, Assef   +5 more
openaire   +2 more sources

Managing imatinib resistance in chronic myeloid leukaemia

Current Opinion in Hematology, 2010
Imatinib mesylate has proven to be an extremely effective and generally well tolerated drug, producing durable responses in most patients with chronic phase chronic myeloid leukaemia. Nonetheless, a minority of patients are resistant or intolerant to imatinib; proposed alternative strategies include imatinib dose escalation, switching to a second ...
Michael, Osborn, Timothy, Hughes
openaire   +2 more sources

Future options for imatinib mesilate-resistant tumors

Expert Opinion on Investigational Drugs, 2007
The outcome of patients with gastrointestinal stromal tumors has been dramatically improved by therapy with imatinib mesilate (imatinib mesylate), a KIT and platelet-derived growth factor (PDGFR) tyrosine kinase inhibitor. Unfortunately, the majority of patients eventually experience disease progression due to drug resistance. Recent elucidation of the
Kamalesh K, Sankhala   +1 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy